drugset / Trial / NCT00532337

Controlled Study of ONO-5334 in Postmenopausal Women With Osteopenia or Osteoporosis

NCT00532337

Phase 2 Completed 285 enrolled Ono Pharma USA Inc
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to evaluate the efficacy and safety of ONO-5334 in postmenopausal women with osteopenia or osteoporosis.

Timeline

Start
2007-10
Primary completion
2010-07
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Alendronic Acid Small molecule 70 mg
Comparator ONO-5334 Unknown 50 mg
Comparator ONO-5334 Unknown 100 mg
Comparator ONO-5334 Unknown 300 mg

Indications